東北大学大学院医学系研究科・医学部

STAFF

Professor

• Nakazawa, ToruProfessor. 中澤 徹 教授 (兼任)
  

Other Faculty / Staff

• Tsuda, Satoru

  Assoc. Prof. 津田 聡 准教授

CONTACT

OUTLINE

The eye is an important sensory organ, and vision accounts for approximately 80% of information received by the five senses. In recent years, the development of OCT, which can visualize the three-dimensional structure of ocular tissues, and molecularly targeted drugs has improved treatment outcomes for various eye diseases. However, the number of patients who have become blind due to glaucoma, a chronic degenerative disease of the optic nerve, is increasing, and it now accounts for 40% of the total number of cases of blindness. Because glaucoma is a multifactorial disease, there is an urgent need to develop new treatments for cases that worsen even with current treatments, which focus on intraocular pressure reduction. Our department aims to establish precision medicine for refractory multifactorial diseases such as glaucoma.
Currently, we are promoting the clinical development of calpain inhibitors and their companion diagnostic drugs, calpain probes (for in vivo imaging methods), as neuroprotective treatments for glaucoma, and we are planning clinical trials to establish precision medicine targeting calpain. We will also collaborate with the Department of Ophthalmology at Tohoku University to conduct drug discovery research using omics data obtained from biological samples. In order to efficiently put research results into practical use, we are building and operating a pharmaceutical-quality disease registry based on regulatory science.
We are also developing AI image diagnostic programs that utilize clinical big data, as well as devices suitable for remote ophthalmology consultations (simple self-examination devices such as slit lamps, fundus cameras, tonometers, and perimeters).

視覚は五感による情報の約80%を占める重要な感覚器です。近年、眼球組織の3次元構造を可視化できるOCTや分子標的治療薬の開発により、様々な眼疾患の治療成績が向上しています。しかし、慢性視神経変性疾患である緑内障は失明患者数が増加し、実に失明患者数の40%を占めています。緑内障は多因子疾患であるため、現状の眼圧下降治療下でも悪化する症例に対して新規治療開発が急務です。本教室では、緑内障を代表とする難治性多因子疾患に対する精密医療の確立を目指しています。
現在、緑内障に対する神経保護治療としてカルパイン阻害薬とそのコンパニオン診断薬であるカルパインプローブ（生体内イメージング法）の臨床開発を進め、カルパインを標的とした精密医療の確立に向けて治験を計画しております。また東北大学眼科学教室と連携し、生体サンプルから得られたオミックス情報を活用した創薬研究を行っていきます。そして研究成果を効率的に実用化するために、レギュラトリーサイエンスに基づき薬事品質の疾患レジストリを構築・運用しております。
その他、臨床のビッグデータを活用したAI画像診断プログラムや眼科遠隔診療に適したデバイス（スリット、眼底写真、眼圧計、視野計などのセルフ簡易検査装置）の開発にも取り組んでいます。

• 

  Birthday party of Prof. Abe
  阿部教授の誕生会

• 

  Showing Sample DDS on OPEN CAMPUS
  オープンキャンパスでDDS作製の見本

• 

  LABO Meeting
  研究室ミーティング

• 

  Introduction of our LABO
  分野紹介ポスター

ARTICLE

Wada S., Tsuda S., Abe M., Nakazawa T., Urushihara H. A quality management system aiming to ensure regulatory-grade data quality in a glaucoma registry (2023) PLoS ONE, 18 (6 June), art. no. e0286669.

Kunikata H., Tawarayama H., Tsuda S., Akaike T., Nakazawa T. Development of an anti-oxidative intraocular irrigating solution based on reactive persulfides (2022) Scientific Reports, 12 (1), art. no. 19243

Asano T., Nagayo Y., Tsuda S., Ito A., Kobayashi W., Fujita K., Sato K., Nishiguchi K.M., Kunikata H., Fujioka H., Kamiya M., Urano Y., Nakazawa T. Companion Diagnosis for Retinal Neuroprotective Treatment by Real-Time Imaging of Calpain Activation Using a Novel Fluorescent Probe (2020) Bioconjugate Chemistry, 31 (9), pp. 2241 - 2251

An G., Omodaka K., Hashimoto K., Tsuda S., Shiga Y., Takada N., Kikawa T., Yokota H., Akiba M., Nakazawa T. Glaucoma Diagnosis with Machine Learning Based on Optical Coherence Tomography and Color Fundus Images (2019) Journal of Healthcare Engineering, 2019, art. no. 4061313

Piao W., Tsuda S., Tanaka Y., Maeda S., Liu F., Takahashi S., Kushida Y., Komatsu T., Ueno T., Terai T., Nakazawa T., Uchiyama M., Morokuma K., Nagano T., Hanaoka K. Development of azo-based fluorescent probes to detect different levels of hypoxia (2013) Angewandte Chemie - International Edition, 52 (49), pp. 13028 - 13032